pramipexole has been researched along with nortriptyline in 4 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (nortriptyline) | Trials (nortriptyline) | Recent Studies (post-2010) (nortriptyline) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 2,289 | 517 | 327 |
| Protein | Taxonomy | pramipexole (IC50) | nortriptyline (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.016 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.0032 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.347 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.095 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.17 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.366 | |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | 1.9 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.95 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.082 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.17 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.047 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.1015 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.019 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.171 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.539 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0032 | |
| Histamine H2 receptor | Homo sapiens (human) | 2.334 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.273 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.051 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.016 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.019 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.17 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.013 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.17 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.17 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.05 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.179 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.136 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.554 | |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | 10 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.678 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.17 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barone, P | 1 |
| Diaz, SH; Dunklee, L; Escalona, R; Fawcett, J; Romo, P; Rush, AJ; Vukelich, J; Yarns, BC | 1 |
2 review(s) available for pramipexole and nortriptyline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of depressive symptoms in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Antiparkinson Agents; Benzothiazoles; Depression; Desipramine; Dopamine Agonists; Humans; Levodopa; Nortriptyline; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2011 |
2 other study(ies) available for pramipexole and nortriptyline
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzothiazoles; Bipolar Disorder; Bupropion; Cohort Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nortriptyline; Pramipexole; Retrospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |